Sunday, January 26, 2014

Pharmaceutical CEO: Cancer Drug Is Only For Westerners Who Can Afford It

The CEO in question is referring to India where the price for one years treatment of Bayers new cancer drug is 47 times the annual income of the average Indian.


That is, so long as you live in the developed world. In a recently published interview in Bloomberg Businessweek, Bayer CEO Marijn Dekkers said that his company’s drug isn’t for poor people.
“We did not develop this medicine for Indians…we developed it for western patients who can afford it,” he said back in December. The quote is quickly making its way across Indian news outlets.


Why make such an assholish comment?
The comment was in response to a decision by an Indian patent court that granted a compulsory license to a local company to reproduce Bayer’s drug. Under Indian patent laws, if a product is not available locally at a reasonable cost, other companies may apply for licenses to reproduce those products at a more affordable price. Nexavar costs an estimated $69,000 for a full year of treatment in India, 41 times the country’s annual per capita income.
In 2012, Indian pharmaceutical company Natco Pharma Ltd. applied for just such a license, and it was granted. The company began reproducing the drug at a 97 percent discount, offering it for just $177. Bayer has been appealing the ruling ever since, and in December Dekkers told Businessweek that he viewed the compulsory license as “essentially theft” before dismissing poor Indian cancer patients.
Pharmaceutical companies naturally exist to make a profit not to help anyone so the CEO of Bayer doesn't feel his corporation should have to offer there cancer drug to those living in less developed countries simply because its citizens have less economic leverage than those living in western nations.


  




No comments:

Translate